Description
OBLIGATION OF FUNDS FOR VENDOR FINAL INVOICE: PHARMACY CONTROLLED SUBSTANCE
Base award description: PHARMACY CONTROLLED SUBSTANCE
Modification chain · 5 transactions
Each row is one published transaction. This action is the obligation recorded on that transaction — a change amount, as USAspending publishes it. Running total is computed by Glassbox VA as the cumulative sum of those amounts up to and including the row, so the last running total equals the award's net obligations shown above. The cumulative-total columns in the source files are not used: they are not frozen per modification.
- Base2016-02-01+$478,141= $478,141
- Mod P000022017-01-10+$7,566= $485,707
- Mod P000032017-08-29-$119,571= $366,136
- Mod P000042017-12-14+$32,857= $398,993
- Mod P000052019-08-21-$40,211= $358,782
| Transaction | Action date | This action (delta) | Running total | Description on this transaction |
|---|---|---|---|---|
| Base | 2016-02-01 | +$478,141 | $478,141 | PHARMACY CONTROLLED SUBSTANCE |
| Mod P00002· OTHER ADMINISTRATIVE ACTION | 2017-01-10 | +$7,566 | $485,707 | PHARMACY CONTROLLED SUBSTANCE |
| Mod P00003· CHANGE ORDER | 2017-08-29 | −$119,571 | $366,136 | DE-OBLIGATION OF REMAINING FUNDS FOR: PHARMACY CONTROLLED SUBSTANCE |
| Mod P00004· OTHER ADMINISTRATIVE ACTION | 2017-12-14 | +$32,857 | $398,993 | OBLIGATION OF FUNDS FOR VENDOR FINAL INVOICE: PHARMACY CONTROLLED SUBSTANCE |
| Mod P00005· CHANGE ORDER | 2019-08-21 | −$40,211 | $358,782 | OBLIGATION OF FUNDS FOR VENDOR FINAL INVOICE: PHARMACY CONTROLLED SUBSTANCE |
Related awards · 11
Awards are related by an explicit link in the data, stated for each group below — never by text similarity. Values are net obligations.
Other VA awards to the same recipient (UEI H3WKVE9VBLY3)
| Award | Office · PSC / listing | Net obligations | FY |
|---|---|---|---|
| 36C24826F0207 | 248-NETWORK CONTRACT OFFICE 8 (36C248) · 6505 · DRUGS AND BIOLOGICALS | $183,903 | FY2026 |
| 36C24826F0187 | 248-NETWORK CONTRACT OFFICE 8 (36C248) · 6505 · DRUGS AND BIOLOGICALS | $36,781 | FY2026 |
| 36C25226F0318 | 252-NETWORK CONTRACT OFFICE 12 (36C252) · 6505 · DRUGS AND BIOLOGICALS | $85,484 | FY2026 |
| 36C24826F0091 | 248-NETWORK CONTRACT OFFICE 8 (36C248) · 6505 · DRUGS AND BIOLOGICALS | $147,122 | FY2026 |
| 36C24826F0037 | 248-NETWORK CONTRACT OFFICE 8 (36C248) · 6505 · DRUGS AND BIOLOGICALS | $124,240 | FY2026 |
| 36C24824F0327 | 248-NETWORK CONTRACT OFFICE 8 (36C248) · 6505 · DRUGS AND BIOLOGICALS | $391,583 | FY2024 |
Other recipients under 6505 from 247-NETWORK CONTRACT OFFICE 7 (36C247) (most recent first)
| Award | Recipient | Office | Net obligations | FY |
|---|---|---|---|---|
| 36C24726P0690 | SINA DRUG LLC | 247-NETWORK CONTRACT OFFICE 7 (36C247) | $188,463 | FY2026 |
| 36C24726N0211 | BOSTON SCIENTIFIC CORP | 247-NETWORK CONTRACT OFFICE 7 (36C247) | $248,982 | FY2026 |
| 36C24726F0100 | AMICUS THERAPEUTICS US, LLC | 247-NETWORK CONTRACT OFFICE 7 (36C247) | $228,396 | FY2026 |
| 36C24726F0053 | EXELAN PHARMACEUTICALS INC | 247-NETWORK CONTRACT OFFICE 7 (36C247) | $4,765,853 | FY2026 |
| 36C24726F0043 | AMICUS THERAPEUTICS US, LLC | 247-NETWORK CONTRACT OFFICE 7 (36C247) | $109,456 | FY2026 |
Cite as: Glassbox VA record view · VA contract (USAspending / FPDS) · CONT_AWD_VA24716F0601_3600_V797D50358_3600 · retrieved 2026-09-26.